• 1
    Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990; 8: 17771781.
  • 2
    Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983; 43: 34033407.
  • 3
    Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986; 4: 400407.
  • 4
    Stoter G, Sylvester R, Sleijfer DT, et al. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res. 1987; 47: 27142718.
  • 5
    Droz JP, Kramar A, Ghosn M, et al. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer. 1988; 62: 564568.
  • 6
    Mead GM, Stenning SP, Parkinson MC, et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992; 10: 8594.
  • 7
    International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15: 594603.
  • 8
    Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998; 16: 12871293.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 10
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 11
    Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol. 1995; 13: 11701176.
  • 12
    Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 1990; 322: 14251429.
  • 13
    Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst. 1993; 85: 3640.
  • 14
    Bredeson CN, Barnett MJ, Horsman DE, et al. Therapy-related acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary. Leuk Lymphoma. 1993; 11: 141145.
  • 15
    Fong CT, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1987; 28: 5576.
  • 16
    Einhorn LH, Williams SD, Troner M, et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med. 1981; 305: 727731.
  • 17
    Stoter G, Sleyfer DT, ten Bokkel Huinink WW, et al. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1986; 4: 11991206.
  • 18
    Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987; 316: 14351440.
  • 19
    Culine S, Kerbrat P, Bouzy J, et al. Are 3 cycles of bleomycin, etoposide and cisplatin (3bep) or 4 cycles of etoposide and cisplatin (4ep) equivalent regimens for patients (pts) with good-risk metastatic non seminomatous germ cell tumors (NSGCT)? Preliminary results of a randomized trial [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 309a.
  • 20
    Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989; 7: 387391.
  • 21
    Loehrer PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995; 13: 470476.
  • 22
    Kollmannsberger C, Nichols C, Meisner C, et al. Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis’ germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol. 2000; 11: 11151120.